Dexamethasone, a synthetic glucocorticoid, is frequently included in the medium of cultured hepatocytes to improve their survival and function. In most experimental models, dexamethasone inhibits hepatocyte growth in vivo. For example, when injected into the rat, dexamethasone inhibits the striking increase in hepatocyte proliferation that occurs after 70% hepatectomy (28) or in transplanted livers following cold preservation and reperfusion (13) . Likewise, dexamethasone has been reported to inhibit the proliferation of rat hepatocytes (35) (34) and liver derived cell lines (24) . In primary hepatocyte culture, however, other investigators have reported that dexamethasone enhances epidermal growth factor (EGF)-stimulated DNA synthesis (30) (26) . We hypothesized that these divergent observations result from differential effects of dexamethasone on one or more components of EGF receptor signaling.
Fetal hepatocytes express three of the four ErbB tyrosine kinase receptors (EGFr, ErbB2, and ErbB3), but by three weeks of age, ErbB2 is largely extinguished (10) . When it binds ligands of the EGF/ TGF family, EGFr can interact with other ErbB proteins to form activated homo (EGFr/EGFr)-or hetero (EGFr/ErbB2 or EGFr/ErbB3) dimers. In contrast, ErbB2 and ErbB3 cannot form active homodimers, and must dimerize with each other or with EGFr to form active tyrosine kinase signaling complexes. ErbB2 is structurally unable to bind an extracellular ligand, and ErbB3, which is the receptor for heregulin (Hrg) peptides, has an inactive tyrosine kinase domain. Relative changes in the cell surface expression of individual ErbB proteins can affect cellular signaling outcomes in response to EGF or Hrg peptides (10) .
We recently showed that expression of these ErbB proteins changes as hepatocytes adapt to primary culture (10) (31). For example, adult hepatocytes, cultured for 24h in the presence of insulin and/or EGF, begin to express ErbB2, which is normally expressed in fetal and neonatal but not adult liver (10) . EGF-or TGF -stimulated DNA synthesis in adult rat hepatocytes requires the presence of ErbB2 in a heterodimer with EGFr (31). The induction of ErbB2 is the likely explanation for the long lag phase (> 40 h from the time of plating) required for hepatocytes to initiate DNA synthesis in response to EGF.
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Since the activated glucocorticoid receptor frequently acts as a transcription factor, altering gene expression, we hypothesized that dexamethasone blunts EGF or TGF stimulated DNA synthesis by inhibiting the ErbB2 induction. Given the temporal changes of ErbB protein expression in vitro, we further speculated that the overall influence of dexamethasone on the hepatocellular response to EGF-type ligands depends on the time of growth factor addition. Our analysis of prior work suggested that the stimulatory effects of dexamethasone occurred when EGF and dexamethasone were added simultaneously at the beginning of the culture period (30). In contrast, the inhibitory action occurred when isolated hepatocytes were plated in a high concentration of dexamethasone for at least 24 h before EGF exposure (35) .
In this paper, we show that the inhibitory effect of dexamethasone on EGF-stimulated DNA synthesis in cultured rat hepatocytes does indeed depend on the time of growth factor addition.
Furthermore, our work provides a molecular basis for the inhibitory effect by showing that the concentration of dexamethasone alters not only the expression and interaction of the ErbB proteins themselves, but also a number of positive and negative growth regulatory proteins in ErbB-regulated signaling pathways.
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EXPERIMENTAL PROCEDURES
Peptides, Reagents, and Radiochemicals. Synthetic rat TGF was from Peninsula Laboratories Inc. (Belmont, CA). Insulin (Novolin® R) was from Novo Nordisk Pharmaceuticals, Inc. (Princeton, NJ). 3 [H]-Thymidine (6 Ci/mmol,) was from Perkin Elmer Life Science, Inc. (Boston, MA). Dexamethasone, pyruvate, bovine serum albumin (fatty acid-free), Percoll, and all buffer reagents were from Sigma (St.
Louis, MO). Protein G-Sepharose and ECL reagents were from Pierce (Rockford, IL). Nitrocellulose membranes were from Osmonics (Minnetonka, MN). Primary Cell Cultures. Hepatocytes were isolated from the livers of male rats between 10:00 and 11:30 AM to control for circadian variation using a two-stage, collagenase isolation protocol (9) . To reduce nonhepatocyte contamination, cells were sedimented through Percoll (9) . We plated cells free medium, growth factors, or dexamethasone. In some experiments, growth factor was added at different times after the change from plating to growth medium.
Immunoprecipitation and Western Blotting. Hepatocytes were lysed in TGH buffer (20mM HEPES, 1% Triton X-100, 10% glycerol 50mM NaCl). This buffer included protease inhibitors (1mM PMSF, 1mM sodium orthovanadate, 10µg/ml aprotinin and 1µg/ml leupeptin) as well as phosphatase inhibitors (10mM sodium molybdate and 10mM -glycerol phosphate). Lysates were microfuged at 20,800 x g for 30 min., and then immunoblotted or immunoprecipitated as previously described (4, 10) . We normalized immunoprecipitations or immunoblots by using equal amounts of protein, as determined by either the Bio-Rad DC Protein Assay (Bio-Rad Laboratories; Hercules, CA) or the Micro BCA protein assay (Pierce Biotechnology, Inc., Rockford, IL). After each transfer, we confirmed equal protein loading and transfer by Ponceau S staining of immunoblots, scanning the image for future reference. Immunoreactive signal was detected using the ECL method (Pierce Biotechnology, Inc., Rockford, IL). We performed densitometry using an Epson scanner with Biosoft Quantiscan Software or the Image J program (1).
DNA Synthesis Assays. Cells were exposed to the Williams' Medium E for varying periods of time before the addition of TGF (typically at a concentration of 5-7.5 nM; TGF was used in place of EGF because unlike EGF, which targets EGFr for lysosomal degradation, TGF promotes recycling of Page 6 of 28 internalized EGFr to the hepatocyte surface (31). After stimulation, the cells were refed with medium containing specified growth factors and 1 µCi/ml of [ 3 H-methyl] thymidine. In some experiments, the time of addition of TGF after cell plating varied. After labeling for 24-48 h, cells were harvested, and the incorporation of tracer was determined as detailed previously (9) . The results of assays in triplicate are expressed as the specific activity of the DNA (dpm/µg DNA ± S.D.).
Statistical Analysis. Statistical analysis was performed using an unpaired, two tailed Student's ttest assuming equal variances between compared groups. To define the kinetics of dexamethasone suppression of EGF-mediated DNA synthesis, we exposed cells to two different concentrations of dexamethasone and then added TGF at different times after plating, evaluating DNA synthesis between 48 and 96 h. To confirm these effects, we used antibodies that specifically recognize discrete tyrosine phosphorylation sites (pY) within the cytoplasmic domains of EGFr or ErbB2. We used antibodies that recognize pY845 and pY1068 for EGFr and pY1112 for ErB2. Parallel blots were performed to find out if the degree of tyrosine phosphorylation correlated to the total ErbB expression level. Dexamethasone inhibits EGF stimulation of ERK1/2 and PI-3 kinase: Phospho-AKT is an indirect measure of the PI3 kinase pathway, a second pathway required for full mitogenic action of EGF (8, 33) .
RESULTS
Prolonged
In the prior experiment, we evaluated whether dexamethasone altered phospho-AKT and were unable to find a consistent effect (data not shown). Since the cells in the prior experiment had not been exposed to fresh TGF for over 24 h (the TGF was added at 0 time for the 24 h group and 48 h for the 72 h group),
we analyzed the acute effect of ligand on AKT phosphorylation in cells cultured in different concentrations of dexamethasone. We examined the acute response of Erk1/2 to EGF in this experiment as well.
In Fig. 5 , we stimulated cells with EGF and under conditions of low or high dexamethasone for 24 or 72 h. We then immunoblotted lysates for the total and phosphorylated forms of ERK1/2 or the singly phosphorylated pAKT (ser 473). As shown in Fig. 5 , irrespective of the dexamethasone concentration, cells cultured for 72 h showed a remarkable increase in the relative amount of total AKT and ERK1/2 compared with 24 h.
When cultured in 10 -8 M or 10 -6 M dexamethasone for 24 h, cells exposed to the highest concentration showed a greater activation of ERK1/2 and AKT that partly correlated with increased expression levels of these molecules at this time. In contrast, by 72 h, cells cultured in the high concentration showed decreased levels of phosphorylated AKT and ERK1/2. Again, the reduced phosphorylation partly correlated with a reduction in the total protein, particularly for ERK1/2.
Dexamethasone induces molecules that inhibit ErbB signaling:
Dexamethasone inhibits proliferation of a number of other cell types using negative effectors, including RALT (2), MPK-1 (14) , and the p85 regulatory subunit of PI3 kinase (17) . We evaluated their expression in hepatocytes as a function of the concentration of dexamethasone (Fig. 6 ). We found that 10
M dexamethasone stabilized the expression of RALT, which normally disappears by 48 h in the absence of dexamethasone. We observed that increasing concentrations of dexamethasone suppressed the expression of the p85 regulatory subunit of PI3 kinase at 24 h of culture. However, this effect was reversed by 72 h. Finally, we found that dexamethasone modulated MPK-1. In contrast to RALT and p85, hepatocytes express little or no MPK-1 unless they are cultured in dexamethasone, which increases MPK-1 in a dose-dependent manner.
DISCUSSION
Dexamethasone has complex effects on cell proliferation in different tissues and cell types (36) . It may augment the effect of a specific growth factor on DNA synthesis in some cell types, but inhibit it in others. For example, it enhances the stimulatory effect of EGF in myoblasts (20) and human diploid fibroblasts, but inhibits the response in 3T3 cells. In a given cell type, the actions of dexamethasone can vary between growth factors. In 3T3 cells, dexamethasone inhibits the growth promoting action of EGF, but potentiates that of fibroblast growth factor (FGF) (18, 19). This suggests that the action of dexamethasone does not target a single cytoplasmic or nuclear mechanism distal to the interaction between growth factors and their cell surface receptors.
Many glucocorticoid effects are both time-and transcription-dependent. However, some actions that depend on glucocorticoid binding to its receptor do not require subsequent binding of the receptor to glucocorticoid response elements within DNA (6, 7, 22) . For example, in the A549 human lung adenocarcinoma cell line, dexamethasone rapidly inhibits recruitment of signaling factors to EGF receptors, increasing the tyrosine phosphorylation of lipocortin in a transcription-independent manner.
The phosphorylated lipocortin binds to GrbB2 docking sites on EGFr, thereby inhibiting the transmission of signals necessary for EGF-stimulated arachidonic acid release and cell growth (12) .
The liver of the intact rat is exquisitely sensitive to the inhibitory actions of dexamethasone and other glucocorticoids, such as hydrocortisone, on cell proliferation. These hormones strongly inhibit DNA synthesis in the developing or regenerating liver and in all liver-derived cell lines (24) . For example, hydrocortisone completely blocks DNA synthesis within a 24 h period when injected into weaning rats. It also partially inhibits DNA synthesis in the regenerating liver of young rats after partial hepatectomy, blunting the regenerative response by about 50%. Recently, it has been shown that dexamethasone inhibits the early regenerative response of the rat liver seen after cold preservation and transplantation (13) . Furthermore, Nagy et al demonstrated that daily injections of dexamethasone (2 mg/kg) immediately before and after 70% hepatectomy in the rat inhibited not only hepatocyte proliferation but also oval cell proliferation and differentiation. Interestingly, in this model, the liver restored its mass by the preferential hypertrophy of periportal hepatocytes. The action of dexamethasone was reversible. Forty h after dexamethasone withdrawal, the enlarged periportal cells entered the S-phase in a synchronized fashion (28) .
Despite these growth inhibitory effects in the liver from the intact rat, dexamethasone or other glucocorticoids are usually included in the growth medium of cultured hepatocytes because they increase cell attachment and survival. They inhibit spontaneous apoptosis through the induction of Bcl-2 and Bclx (4), and they also inhibit the TNF and Fas death receptor-mediated apoptosis through the up-regulation of Flice (29). Some investigators have reported that dexamethasone increases EGF-stimulated DNA synthesis (30) (26) , but others have reported that dexamethasone inhibits it (35) (34). These divergent effects are unrelated to differences in dose since they both varied in a dose-dependent manner. No clear concept to explain these discrepant findings has arisen until now.
In this paper, we show that the timing of the growth factor addition relative to the initial dexamethasone exposure is the critical determinant in defining whether dexamethasone has stimulatory or inhibitory effects on DNA synthesis (Fig. 1A) . This conclusion is supported by the analysis of conflicting papers. Sand et al showed that in hepatocytes treated with insulin and EGF from the time of plating, dexamethasone increased the rate of DNA synthesis by 20-30% (30). In contrast, Vintermyr and Doskeland reported that when cells were exposed to EGF after 20 h of culture, DNA synthesis was inhibited by dexamethasone (34) . The latter authors speculated that the use of collagen coated plates or the inclusion of pyruvate in their media may have been responsible for the discrepancies. We now show that neither collagen nor pyruvate can account for them since they are also components of our culture system. Instead, the inhibitory effect of dexamethasone is not immediate as described for some cell types (12) but requires cell exposure to dexamethasone for as long as 18 hours before growth factor addition (Fig. 1B) .
Very little is known about the mechanisms used by dexamethasone to stimulate or inhibit DNA synthesis in the intact liver and in primary hepatocytes. Several possible explanations have been offered for the inhibitory effect on hepatocytes, including the synthesis and release of a secreted growth inhibitory factor or an effect on the stability of gap junctions and cell contacts, which decrease during states of high cell proliferation, such as liver regeneration (34) . Indeed, others reported that the inhibitory effect of dexamethasone was greater in areas of high cell density, suggesting that cell contact contributed to the effect (34).
We have recently shown that the ErbB expression profile in hepatocytes changes during adaptation to cell culture (31), coinciding with an increased responsiveness to EGF (25) . The proliferative effects of EGF in cultured hepatocytes require the induction of ErbB2 shortly before DNA synthesis rises 48 h after plating. Since the timing of growth factor addition was critical to the inhibitory glucocorticoid effect on DNA synthesis (Fig.1) , we speculated that dexamethasone altered either the expression of the ErbB proteins or downstream signaling pathways. Indeed, Baker et al reported a precedent for a dexamethasone-induced growth altering change in the cell surface expression of growth factor receptors (5). In human diploid fibroblasts, dexamethasone enhanced EGF-stimulated DNA synthesis while increasing 125 I-EGF binding to surface membranes by 1.5 fold at 8 h after addition and by 2-fold at 32 h.
We now report that dexamethasone has far-reaching effects on ErbB expression and activation (Figs. 2 and 3) . Moreover, these changes in ErbB expression resulted in a decrease in EGF-stimulated tyrosine phosphorylation of EGFr and ErbB2 (Fig.3) . Dexamethasone also altered signaling downstream of the ErbB proteins, including the ERK and PI3 kinase pathways (Figs, 4 and 5). Both pathways are required for EGF to stimulate DNA synthesis in cultured hepatocytes based on studies using pharmacologic or genetic inhibitors (8) (33) . Dexamethasone at a high dose suppressed both pathways in cells treated for 72 h of culture.
Other groups have shown that dexamethasone suppresses these pathways in other cell types through negative effectors that either directly bind to the ErbB proteins or indirectly inhibit ErbB action by inhibiting ERK or PI3 kinase. Dexamethasone can induce unique adaptor-like molecules that bind to discrete regions of the ErbB cytoplasmic domains and inhibit signaling. Such proteins include RALT, (also known as gene 33 and MiG-6) and Dok-1 (21) . RALT suppresses the tyrosine kinase activity of both ErbB-2 and EGFR (2, 15, 16, 38) . Dexamethasone also inhibits signaling components downstream from the ligand-ErbB interaction. Inhibition of ERK primarily occurs through the induction of the dual specificity phosphatase MKP-1, which dephosphorylates phosphoserine and phosphothreonine residues within ERK, attenuating the transmission of growth factor signals (14, 23) . Dexamethasone also exerts some of its anti-proliferative and pro-apoptotic effects in certain cell types by upregulating the p85 regulatory subunit and thereby inhibiting PI3K (11, 17, 32) . In hepatocytes, we found that dexamethasone influenced the expression of p85, RALT, and MKP-1 in a manner that generally correlated with its inhibitory effect on DNA synthesis (Fig. 6 ).
Hepatocytes in primary culture are a popular model to study and define the regulation of hepatocyte growth, function, and signaling. However, primary hepatocytes are a dynamic system that adapt to the conditions of culture. In doing so, they undergo striking changes in the expression patterns of 
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We acknowledge the generous support of student research stipend from the Vanderbilt Diabetes Center to RB. This work was supported by DK 53804 (to WER). -8 or 10 -6 M dexamethasone for 24 or 72 h and then exposed them to EGF (50 nM) for 0, 1.5, 3, or 6 min. This figure shows a representative experiment. Note that 10 -6 M dexamethasone increases the total amount of AKT and ERK at 24 h. Both AKT and ERK increase at 72 h, but the increase in the total amount of ERK1, but not ERK2 or AKT, is suppressed by the highest concentration of dexamethasone. All of the phosphorylated forms of ERK1/2 and AKT are diminished in cells culture in the highest concentrations of dexamethasone at 72 h, which indicates that other mechanisms besides protein density account for the inhibitory effect of dexamethasone in this model. 
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